Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Refractory Malignancy”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Active Not RecruitingNCT05334329
What this trial is testing

Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors

Who this might be right for
Advanced Lung Non-Small Cell CarcinomaMetastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell Carcinoma+8 more
University of California, Irvine 6
Early research (Phase 1)Looking for participantsNCT07225439
What this trial is testing

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Non Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma+7 more
Paolo Caimi, MD 15
Testing effectiveness (Phase 2)Active Not RecruitingNCT03600701
What this trial is testing

Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

Who this might be right for
Metastatic Lung Non-Small Cell CarcinomaRecurrent Lung Non-Small Cell CarcinomaRefractory Lung Non-Small Cell Carcinoma+1 more
National Cancer Institute (NCI) 53
Testing effectiveness (Phase 2)Ended earlyNCT06018129
What this trial is testing

A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma

Who this might be right for
Classical Hodgkin LymphomaNon-Hodgkin Lymphoma
Genmab 9
Early research (Phase 1)Looking for participantsNCT07668557
What this trial is testing

Anti-CD33-CLL1 CAR-T Cells (ICG415) for the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
iCell Gene Therapeutics 18
Testing effectiveness (Phase 2)Looking for participantsNCT07032129
What this trial is testing

Sequential CAR-T Cells Targeting BCMA/GPRC5D in Patients With Relapsed/ Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaMultiple Myeloma in RelapseMultiple Myeloma Progression+1 more
Essen Biotech 60
Early research (Phase 1)Study completedNCT03739931
What this trial is testing

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

Who this might be right for
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or LymphomaDose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
ModernaTX, Inc. 134
Early research (Phase 1)Looking for participantsNCT06654037
What this trial is testing

Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer

Who this might be right for
Metastatic Microsatellite Stable Colorectal CarcinomaRefractory Microsatellite Stable Colorectal CarcinomaStage IV Colorectal Cancer AJCC v8
National Cancer Institute (NCI) 39
Testing effectiveness (Phase 2)Active Not RecruitingNCT04984837
What this trial is testing

Study of Lacutamab in Peripheral T-cell Lymphoma

Who this might be right for
Peripheral T Cell LymphomaRelapse/Recurrence
The Lymphoma Academic Research Organisation 49
Early research (Phase 1)Study completedNCT02482532
What this trial is testing

Vaccine Enriched, Autologous, Activated T-Cells Directed to Tumor in Patients With Relapsed/Refractory Melanoma

Who this might be right for
Melanoma
Gary Doolittle 7
Testing effectiveness (Phase 2)Looking for participantsNCT05934513
What this trial is testing

GFH009 Monotherapy in Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

Who this might be right for
Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
Genfleet Therapeutics (Shanghai) Inc. 95
Testing effectiveness (Phase 2)Study completedNCT01101880
What this trial is testing

Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)+8 more
University of Washington 50
Not applicableLooking for participantsNCT05620680
What this trial is testing

CD7 CAR-T Cells in T-cell Lymphoma/Leukemia

Who this might be right for
T Lymphoblastic Leukemia/Lymphoma
Shenzhen University General Hospital 20
Early research (Phase 1)Study completedNCT05548088
What this trial is testing

LILRB4 STAR-T Cells in the Treatment of R/R AML/CMML

Who this might be right for
Relapsed/Refractory Acute Myeloid Leukemia and Chronic Granulocytic-Mononocytic Leukemia
Peking University People's Hospital 11
Testing effectiveness (Phase 2)Study completedNCT07505615
What this trial is testing

A Phase I-II Study of Novel Oncolytic Virus VG161 Via Intravesical Instillation for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer

Who this might be right for
NMIBC
Ding-Wei Ye 20
Early research (Phase 1)Study completedNCT02355535
What this trial is testing

Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1

Who this might be right for
Solid TumorPancreatic Neuroendocrine TumorNeuroendocrine Tumors
Vanquish Oncology, Inc. 48
Testing effectiveness (Phase 2)Study completedNCT00381940
What this trial is testing

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Who this might be right for
Adult Lymphocyte Depletion Hodgkin LymphomaAdult Lymphocyte Predominant Hodgkin LymphomaAdult Mixed Cellularity Hodgkin Lymphoma+17 more
National Cancer Institute (NCI) 26
Testing effectiveness (Phase 2)Looking for participantsNCT06542250
What this trial is testing

Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

Who this might be right for
B-cell Malignancies
AstraZeneca 174
Testing effectiveness (Phase 2)Ended earlyNCT00522990
What this trial is testing

Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaChronic Myeloid Leukemia+2 more
Astex Pharmaceuticals, Inc. 48
Early research (Phase 1)Study completedNCT02975882
What this trial is testing

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Who this might be right for
Childhood Solid NeoplasmRecurrent Malignant Solid NeoplasmRecurrent Primary Central Nervous System Neoplasm+2 more
Children's Oncology Group 33
Next Page